31812554Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto NThe Lancet. OncologyAntibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Drug Resistance, Neoplasm; Lymphoma; Melanoma; Neoplasm Recurrence, Local; NeoplasmsAdolescent; Child; Child, Preschool; Cohort Studies; Female; Follow-Up Studies; Humans; Infant; Male; Prognosis; Salvage Therapy; Survival RatePembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 01; 21(1):121-133.Lancet Oncol2019-12-04T00:00:002019Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000293Living Beings111389680.40057AdolescentD002648Living Beings93969130.440068ChildD002675Living Beings65236080.594978Child, PreschoolD007223Living Beings60430360.613076InfantD005260Physiology1992444050.191184FemaleAuthorship 134741110.1853390.1853391authors10.2520has subject areaD015331Concepts & IdeasProcedures72727590.604878Cohort StudiesD006801Living Beings2262862810.130064HumansD008297Physiology1931408600.201635MaleD019008Physiology1805890.751147Drug Resistance, NeoplasmD016879Procedures972320.889684Salvage TherapyD008223Disorders1142620.859127LymphomaD008545Disorders1634540.720246MelanomaD009364Disorders33613050.619886Neoplasm Recurrence, LocalD060890Chemicals & Drugs952500.845952B7-H1 AntigenD011379Procedures74536690.561484PrognosisD061067Chemicals & Drugs2139290.656201Antibodies, Monoclonal, HumanizedD015996Concepts & Ideas45518560.724919Survival RateD000074322851850.820857Antineoplastic Agents, ImmunologicalD005500Procedures76836160.590143Follow-Up StudiesD009369Disorders55628890.338498NeoplasmsPediatricsUniversity of ChicagoSusan L.CohnxGFmA69EOfnamXNnYUHhvWD+6g==Susan L. Cohn41.78927490000000-87.601250000000001250Cohn, Susan L.Professortrue1ProfessorProfessor